These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 22471115)

  • 1. [New european guidelines for dyslipidemia].
    Riesen WF; Virgini V; Vogt B; Rodondi N
    Rev Med Suisse; 2012 Mar; 8(331):525-6, 528-30. PubMed ID: 22471115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dyslipidemia therapy update: the importance of full lipid profile assessment.
    Menown IB; Murtagh G; Maher V; Cooney MT; Graham IM; Tomkin G
    Adv Ther; 2009 Jul; 26(7):711-8. PubMed ID: 19649582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New ESC/EAS Guidelines for the management of dyslipidaemias - any controversies behind the consensus?
    Reiner Z
    Eur J Cardiovasc Prev Rehabil; 2011 Oct; 18(5):724-7. PubMed ID: 21945917
    [No Abstract]   [Full Text] [Related]  

  • 5. [New European guidelines for the management of dyslipidaemia in cardiovascular prevention].
    Descamps OS; De Backer G; Annemans L; Muls E; Scheen AJ; ;
    Rev Med Liege; 2012 Mar; 67(3):118-27. PubMed ID: 22611827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular risk stratification according to the 2003 ESH-ESC guidelines in uncomplicated patients with essential hypertension: comparison with the 1999 WHO/ISH guidelines criteria.
    Cuspidi C; Meani S; Salerno M; Severgnini B; Fusi V; Valerio C; Catini E; Magrini F; Zanchetti A
    Blood Press; 2004; 13(3):144-51. PubMed ID: 15223722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
    ; Catapano AL; Reiner Z; De Backer G; Graham I; Taskinen MR; Wiklund O; Agewall S; Alegria E; Chapman MJ; Durrington P; Erdine S; Halcox J; Hobbs R; Kjekshus J; Perrone Filardi P; Riccardi G; Storey RF; Wood D;
    Atherosclerosis; 2011 Jul; 217 Suppl 1():S1-44. PubMed ID: 21723445
    [No Abstract]   [Full Text] [Related]  

  • 8. [New European clinical guidelines on dyslipidemias].
    Matikainen N; Taskinen MR
    Duodecim; 2012; 128(16):1651-62. PubMed ID: 23025148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenesis and management of the dyslipidemia of the metabolic syndrome.
    Raal FJ
    Metab Syndr Relat Disord; 2009 Apr; 7(2):83-8. PubMed ID: 19400742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The new 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk: comparison with the ESC/EAS recommendations for the management of dyslipidemias].
    Catapano AL; Averna M; Faggiano P; Novo S
    G Ital Cardiol (Rome); 2014 Jan; 15(1):19-20. PubMed ID: 24503730
    [No Abstract]   [Full Text] [Related]  

  • 11. [How I treat ... dyslipidemia according to the cardiovascular risk profile].
    Descamps OS; Scheen AJ; De Backer G; Annemans L; Muls E;
    Rev Med Liege; 2012 Apr; 67(4):167-73. PubMed ID: 22670442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Low HDL-cholesterol--an important risk factor for cardiovascular diseases].
    Reiner Z; Muacević-Katanec D; Katanec D; Tedeschi-Reiner E
    Lijec Vjesn; 2011; 133(3-4):111-6. PubMed ID: 21612108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A simple multiplier to calculate the impact of HDL cholesterol on cardiovascular risk estimation using SCORE.
    Descamps OS; Cooney MT; De Backer G; Graham I
    Atherosclerosis; 2012 Jun; 222(2):564-6. PubMed ID: 22560327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lipid management--treatment goal and strategy].
    Koshiyama H
    Nihon Rinsho; 2006 Nov; 64(11):2102-6. PubMed ID: 17087303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of international guidelines on the management of cardiovascular risk factors in diabetic patients with peripheral arterial disease.
    Margeta C; Giurgea A; Hammer A; Schlager O; Zehetmayer S; Koppensteiner R; Willfort-Ehringer A
    Int Angiol; 2009 Jun; 28(3):175-80. PubMed ID: 19506537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.
    Laforest L; Souchet T; Moulin P; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Van Ganse E
    Arch Cardiovasc Dis; 2009 Jan; 102(1):43-50. PubMed ID: 19233108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should raising high-density lipoprotein cholesterol be a matter of debate?
    Athyros VG; Katsiki N; Karagiannis A; Mikhailidis DP
    J Cardiovasc Med (Hagerstown); 2012 Apr; 13(4):254-9. PubMed ID: 22367577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atherogenic dyslipidemia.
    Hayden MR
    J Cardiometab Syndr; 2006; 1(3):166-7. PubMed ID: 17679821
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.